HK1245139A1 - 用於在局部給藥位點改進藥物組合物的滯留的組合物和方法 - Google Patents

用於在局部給藥位點改進藥物組合物的滯留的組合物和方法

Info

Publication number
HK1245139A1
HK1245139A1 HK18104837.9A HK18104837A HK1245139A1 HK 1245139 A1 HK1245139 A1 HK 1245139A1 HK 18104837 A HK18104837 A HK 18104837A HK 1245139 A1 HK1245139 A1 HK 1245139A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
pharmaceutical composition
local administration
administration site
Prior art date
Application number
HK18104837.9A
Other languages
English (en)
Inventor
T‧R‧泰斯
K‧W‧伯頓
Original Assignee
贏創有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 贏創有限公司 filed Critical 贏創有限公司
Publication of HK1245139A1 publication Critical patent/HK1245139A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S260/00—Chemistry of carbon compounds
    • Y10S260/31—Ionic cross-link

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18104837.9A 2010-03-29 2018-05-16 用於在局部給藥位點改進藥物組合物的滯留的組合物和方法 HK1245139A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31857410P 2010-03-29 2010-03-29

Publications (1)

Publication Number Publication Date
HK1245139A1 true HK1245139A1 (zh) 2018-08-24

Family

ID=44080321

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18104837.9A HK1245139A1 (zh) 2010-03-29 2018-05-16 用於在局部給藥位點改進藥物組合物的滯留的組合物和方法

Country Status (11)

Country Link
US (1) US9504643B2 (zh)
EP (1) EP2552416B1 (zh)
JP (2) JP2013523752A (zh)
CN (2) CN103068371A (zh)
AU (1) AU2011238646B2 (zh)
CA (1) CA2794328C (zh)
ES (1) ES2655592T3 (zh)
HK (1) HK1245139A1 (zh)
IL (1) IL222092B (zh)
RU (1) RU2012145811A (zh)
WO (1) WO2011126839A2 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
US20120321665A1 (en) * 2009-12-14 2012-12-20 Benaroya Research Institute At Virginia Mason Compositions and methods for treating airway inflammatory diseases
SG10201602665UA (en) 2011-04-05 2016-05-30 Edge Therapeutics Intraventricular Drug Delivery System For Improving Outcome After A Brain Injury Affecting Cerebral Blood Flow
US9399019B2 (en) 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
DE102015220583A1 (de) * 2015-10-21 2017-04-27 Tetec Tissue Engineering Technologies Ag Medizinische Zusammensetzung und medizinisches Hydrogel zur Anwendung bei der Vorbeugung und/oder Behandlung einer Erkrankung der Facettengelenke und/oder zur Anwendung beim Ersatz und/oder der Regeneration von Facettengelenkknorpel
US20190264008A1 (en) 2016-10-31 2019-08-29 Kewpie Corporation Gel Composition and Method for Producing Same
CA3055985A1 (en) 2017-03-22 2018-09-27 Genentech, Inc. Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
EP3678704A4 (en) 2017-09-05 2021-09-01 Torque Therapeutics, Inc. REVERSIBLE LINKS AND THEIR USE
EP3678701A4 (en) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. THERAPEUTIC PROTEIN COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1476088A (en) * 1975-04-03 1977-06-10 Ici Ltd Carbodiimides
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
JP3283288B2 (ja) * 1991-03-08 2002-05-20 電気化学工業株式会社 生理活性ペプチド製剤
GR920100122A (el) 1991-04-05 1993-03-16 Ethicon Inc Πολυσακχαρίτες οι οποίοι περιέχουν καρβοξύλιο με σταυροειδείς δεσμούς δια την πρόληψιν της προσφύσεως.
US6150581A (en) * 1995-06-07 2000-11-21 United States Surgical Corporation Chitosan/alginate anti-adhesion barrier
JP3898783B2 (ja) * 1996-08-26 2007-03-28 久光製薬株式会社 生体内分解性ヒアルロン酸架橋ゲル組成物及び生体内分解性ヒアルロン酸架橋ゲル製剤
AU1384199A (en) * 1997-11-07 1999-05-31 Chiron Corporation Method for producing igf-1 sustained-release formulations
US6630457B1 (en) 1998-09-18 2003-10-07 Orthogene Llc Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
US6899889B1 (en) * 1998-11-06 2005-05-31 Neomend, Inc. Biocompatible material composition adaptable to diverse therapeutic indications
GB9902652D0 (en) 1999-02-05 1999-03-31 Fermentech Med Ltd Process
US6352667B1 (en) 1999-08-24 2002-03-05 Absorbable Polymer Technologies, Inc. Method of making biodegradable polymeric implants
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
WO2001047501A1 (en) 1999-12-29 2001-07-05 Nanodelivery, Inc. Drug delivery system exhibiting permeability control
JP4755795B2 (ja) 2000-02-03 2011-08-24 電気化学工業株式会社 ヒアルロン酸ゲルの製造方法及びそれを含有する医用材料
CA2407235A1 (en) 2000-04-28 2001-11-08 Fziomed, Inc. Hemostatic compositions of polyacids and polyalkylene oxides and methods for their use
AU3104102A (en) * 2000-12-18 2002-07-01 Univ Texas Local regional chemotherapy and radiotherapy using in situ hydrogel
TW200307011A (en) * 2002-04-18 2003-12-01 Chugai Pharmaceutical Co Ltd Hyaluronic acid modifier
JP2006500395A (ja) * 2002-09-09 2006-01-05 エンド ファーマシューティカルズ インコーポレーテッド 組み合わされた即時放出及び徐放の鎮痛組成物
EP1562630A4 (en) * 2002-10-31 2009-02-18 Univ Northwestern INJECTIONABLE BIOADHESIVE POLYMERIC HYDROGELS AND ASSOCIATED METHODS OF ENZYMATIC PREPARATION
US7601704B2 (en) 2003-11-03 2009-10-13 University Of North Texas Process for synthesizing oil and surfactant-free hyaluronic acid nanoparticles and microparticles
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
WO2005070333A1 (en) * 2004-01-13 2005-08-04 Orthobiologica, Inc. Drug delivery to a joint
EP1796690A4 (en) * 2004-09-22 2011-08-03 Cartilix Inc KNORPELFÜLLVORRICHTUNG
CA2583373C (en) 2004-10-12 2013-09-03 Fmc Biopolymer As Self-gelling alginate systems and uses thereof
AU2005299748B2 (en) 2004-10-21 2009-04-09 Tgel Bio Co., Ltd In situ controlled release drug delivery system
US8303972B2 (en) * 2005-04-19 2012-11-06 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
ITPI20050071A1 (it) * 2005-06-20 2006-12-21 Giuseppe Calvosa Composizione biocompatibile per la sostituzione/rigenerazione di tessuti
US20070141160A1 (en) 2005-12-15 2007-06-21 Brown Laura J Method of treatment for osteoarthritis by local intra-articular injection of microparticles
ES2397712T3 (es) * 2006-01-18 2013-03-08 Qps, Llc Composiciones farmacéuticas con estabilidad reforzada
WO2007120818A2 (en) * 2006-04-12 2007-10-25 Massachusetts Institute Of Technology Compositions and methods for inhibiting adhesions
WO2008041246A2 (en) * 2006-10-05 2008-04-10 Panacea Biotec Ltd. Injectable depot composition and its' process of preparation

Also Published As

Publication number Publication date
IL222092B (en) 2019-02-28
US20110236497A1 (en) 2011-09-29
EP2552416A2 (en) 2013-02-06
JP2013523752A (ja) 2013-06-17
CA2794328A1 (en) 2011-10-13
AU2011238646B2 (en) 2016-02-04
JP2016011312A (ja) 2016-01-21
CN107260684A (zh) 2017-10-20
CA2794328C (en) 2018-01-16
US9504643B2 (en) 2016-11-29
ES2655592T3 (es) 2018-02-20
WO2011126839A2 (en) 2011-10-13
CN103068371A (zh) 2013-04-24
AU2011238646A1 (en) 2012-10-11
WO2011126839A3 (en) 2012-05-03
JP6203224B2 (ja) 2017-09-27
EP2552416B1 (en) 2017-10-25
RU2012145811A (ru) 2014-05-10

Similar Documents

Publication Publication Date Title
HK1245139A1 (zh) 用於在局部給藥位點改進藥物組合物的滯留的組合物和方法
EP2747563A4 (en) COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS
EP2661273A4 (en) IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
EP2612655A4 (en) LIQUID COMPOSITIONS OF INSOLUBLE DRUGS AND METHODS OF PREPARING THE SAME
EP2629786A4 (en) COMPOSITIONS FOR THE ADMINISTRATION OF MEDICAMENTS
HK1175947A1 (zh) 醫藥組合物及其製備方法
HK1170166A1 (zh) 提高普拉格雷溶出度的藥物組合物及其製備方法
GB201104473D0 (en) Improved pharmaceutical compositions and methods of delivery
EP2643045A4 (en) THERAPEUTIC PROCESSES AND COMPOSITIONS FOR SOLID FORM DELIVERY
ZA201303988B (en) Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
HU1000069D0 (en) New salts for the preparation of pharmaceutical composition
EP2647380A4 (en) PHARMACEUTICAL COMPOSITION WITH MOMETASON FUROAT AND AZELASTINE HYDROCHLORIDE FOR NASAL ADMINISTRATION
EP2419138A4 (en) GEL COMPOSITIONS FOR THE ADMINISTRATION OF PHARMACEUTICALLY ACTIVE COMPOUNDS
EP2654638A4 (en) COMPOSITION FOR TRANSDERMAL ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY DRUG
HK1183228A1 (zh) 口服藥物治療方法和組合物
PL2642993T3 (pl) Kompozycje rotygotyny lub farmaceutycznie dopuszczalnych soli rotygotyny
EP2616053A4 (en) PHARMACEUTICAL COMPOSITIONS FROM CURCUMIN
IL214420A0 (en) Pharmaceutical compositions comprising tamsulosin and solifenacin for oral administration
IL221742A (en) Oral Pharmaceuticals Containing Debigtran Etxylate
HK1181768A1 (zh) 生物鹼氨基酯衍生物及其藥物組合物
EP2651395A4 (en) PHARMACEUTICAL COMPOSITIONS OF SELECTIVE FACTOR XA INHIBITORS FOR ORAL ADMINISTRATION
EP2560614A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THEIR ADMINISTRATION
HK1182093A1 (zh) 生物鹼氨基酯衍生物及其藥物組合物
HK1181047A1 (zh) 生物鹼氨基酯衍生物及其藥物組合物
HU1000299D0 (en) Nanostructured atorvastatin, its pharmaceutically acceptable salts and pharmaceutical compositions containing them and process for their preparation